RESUMEN
BACKGROUND/AIMS: Pulmonary infections with Pseudomonas aeruginosa (P. aeruginosa) or Staphylococcus aureus (S. aureus) are of utmost clinical relevance in patients with cystic fibrosis, chronic obstructive pulmonary disease, after trauma and burn, upon ventilation or in immuno-compromised patients. Many P. aeruginosa and S. aureus strains are resistant to many known antibiotics and it is very difficult or often impossible to eradicate the pathogens in patient´s lungs. We have recently shown that the sphingoid base sphingosine very efficiently kills many pathogens, including for instance P. aeruginosa, S. aureus or Acinetobacter baumannii, in vitro. In vivo experiments of our group on cystic fibrosis mice indicated that inhalation of sphingosine prevents or eliminates existing acute or chronic pneumonia with P. aeruginosa or S. aureus in these mice. We also demonstrated that sphingosine is safe to use for inhalation up to high doses, at least in mice. To facilitate development of sphingosine to an anti-bactericidal drug that can be used in humans for inhalation, safety data on non-rodents, larger animals are absolutely required. METHODS: Here, we inhaled mini pigs with increasing doses of sphingosine for 10 days and analyzed the uptake of sphingosine into epithelial cells of bronchi as well as into the trachea and lung and the systemic circulation. Moreover, we measured the generation of ceramide and sphingosine 1-phosphate that potentially mediate inflammation, the influx of leukocytes, epithelial cell death and disruption of the epithelial cell barrier. RESULTS: We demonstrate that inhalation of sphingosine results in increased levels of sphingosine in the luminal membrane of bronchi and the trachea, but not in systemic accumulation. Inhaled sphingosine had no side effects up to very high doses. CONCLUSION: In summary, we demonstrate that inhalation of sphingosine results in an increase of sphingosine concentrations in the luminal plasma membrane of tracheal and bronchial epithelial cells. The inhalation has no systemic or local side effects.
Asunto(s)
Antibacterianos/metabolismo , Esfingosina/metabolismo , Administración por Inhalación , Animales , Antibacterianos/farmacología , Bronquios/metabolismo , Bronquios/patología , Ceramidas/análisis , Humanos , Pulmón/patología , Lisofosfolípidos/análisis , Espectrometría de Masas , Pseudomonas aeruginosa/efectos de los fármacos , Esfingosina/análogos & derivados , Esfingosina/análisis , Esfingosina/farmacología , Staphylococcus aureus/efectos de los fármacos , Porcinos , Porcinos Enanos , Tráquea/metabolismo , Tráquea/patologíaRESUMEN
Farber disease is a rare lysosomal storage disorder resulting from acid ceramidase deficiency and subsequent ceramide accumulation. No treatments for Farber disease are clinically available, and affected patients have a severely shortened lifespan. We have recently reported a novel acid ceramidase deficiency model that mirrors the human disease closely. Acid sphingomyelinase is the enzyme that generates ceramide upstream of acid ceramidase in the lysosomes. Using our acid ceramidase deficiency model, we tested if acid sphingomyelinase could be a potential novel therapeutic target for the treatment of Farber disease. A number of functional acid sphingomyelinase inhibitors are clinically available and have been used for decades to treat major depression. Using these as a therapeutic for Farber disease, thus, has the potential to improve central nervous symptoms of the disease as well, something all other treatment options for Farber disease can't achieve so far. As a proof-of-concept study, we first cross-bred acid ceramidase deficient mice with acid sphingomyelinase deficient mice in order to prevent ceramide accumulation. Double-deficient mice had reduced ceramide accumulation, fewer disease manifestations, and prolonged survival. We next targeted acid sphingomyelinase pharmacologically, to test if these findings would translate to a setting with clinical applicability. Surprisingly, the treatment of acid ceramidase deficient mice with the acid sphingomyelinase inhibitor amitriptyline was toxic to acid ceramidase deficient mice and killed them within a few days of treatment. In conclusion, our study provides the first proof-of-concept that acid sphingomyelinase could be a potential new therapeutic target for Farber disease to reduce disease manifestations and prolong survival. However, we also identified previously unknown toxicity of the functional acid sphingomyelinase inhibitor amitriptyline in the context of Farber disease, strongly cautioning against the use of this substance class for Farber disease patients.
Asunto(s)
Lipogranulomatosis de Farber/enzimología , Esfingomielina Fosfodiesterasa/deficiencia , Ceramidasa Ácida/metabolismo , Amitriptilina/farmacología , Animales , Ceramidas/metabolismo , Citocinas/metabolismo , Lipogranulomatosis de Farber/patología , Ratones Endogámicos C57BL , Esfingomielina Fosfodiesterasa/metabolismo , Análisis de Supervivencia , Aumento de Peso/efectos de los fármacosRESUMEN
Farber disease (FD) is a rare lysosomal storage disorder resulting from acid ceramidase deficiency and subsequent ceramide accumulation. No treatments are clinically available and affected patients have a severely shortened lifespan. Due to the low incidence, the pathogenesis of FD is still poorly understood. Here, we report a novel acid ceramidase mutant mouse model that enables the study of pathogenic mechanisms of FD and ceramide accumulation. Asah1tmEx1 mice were generated by deletion of the acid ceramidase signal peptide sequence. The effects on lysosomal targeting and activity of the enzyme were assessed. Ceramide and sphingomyelin levels were quantified by liquid chromatography tandem-mass spectrometry (LC-MS/MS) and disease manifestations in several organ systems were analyzed by histology and biochemistry. We show that deletion of the signal peptide sequence disrupts lysosomal targeting and enzyme activity, resulting in ceramide and sphingomyelin accumulation. The affected mice fail to thrive and die early. Histiocytic infiltrations were observed in many tissues, as well as lung inflammation, liver fibrosis, muscular disease manifestations and mild kidney injury. Our new mouse model mirrors human FD and thus offers further insights into the pathogenesis of this disease. In the future, it may also facilitate the development of urgently needed therapies.
Asunto(s)
Modelos Animales de Enfermedad , Lipogranulomatosis de Farber/patología , Animales , Ceramidas/análisis , Ceramidas/metabolismo , Cromatografía Liquida , Lipogranulomatosis de Farber/metabolismo , Ratones , Ratones Endogámicos C57BL , Esfingomielinas/análisis , Esfingomielinas/metabolismo , Espectrometría de Masas en TándemRESUMEN
Cells transformed by proteins of early regions 1A (E1A) and 1B (E1B) of oncogenic adenovirus serotype 12 (Ad12) grow to tumours in syngeneic, immunocompetent rodents. To gain insight into the mechanisms of oncogenic transformation, we point mutated the first splice donor in the Ad12-E1A gene, leading to the loss of the Ad12-E1A(9.5S) and Ad12-E1A(11S/10S) proteins and to a conservative amino acid (aa) exchange at position aa 30 (valine vs. leucine) in the Ad12-E1A(13S) and Ad12-E1A(12S ) proteins. BMK cells transformed by mutant Ad12-E1A (Ad12-E1Am) plus Ad12-E1B via retrovirus-mediated gene transfer showed features comparable to wild-type Ad12-E1A (Ad12-E1Awt) plus Ad12-E1B-transformed cells: they formed foci in soft agar and produced tumours in immunodeficient nude mice, although after a prolonged latency period. These results suggest that Ad12-E1A(9.5S) and Ad12-E1A(11S/10S) are dispensable for cellular transformation. However, in contrast to Ad12-E1Awt cells, Ad12-E1Am cells failed to grow to tumours in syngeneic, immunocompetent rodents, with the exception of one cell line, which produced tumours in about 50% of the immunocompetent animals. Interestingly, the concentration of the putative tumour suppressor and co-activator p300 was elevated in cell lines expressing high levels of Ad12-E1A and Ad12-E1B due to an increased half-life. These results indicate that p300 is stabilized in Ad12-E1-transformed BMK cells, probably by a mechanism linked to high expression of Ad12-E1A/E1B.